SCHEMBL910369

SCHEMBL910369

CC(C)N[C@H](CCC(=O)O)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 11/20 0.57
NAALAD2 Q9Y3Q0 2/20 0.57
RIMKLA Q8IXN7 1/20 0.57
GGH Q92820 1/20 0.53
CYP1A2 P05177 1/20 0.52
GABRP O00591 2/20 0.46
GABRD O14764 2/20 0.46
GABRA1 P14867 2/20 0.46
GABRB1 P18505 2/20 0.46
GABRG2 P18507 2/20 0.46
GABRB3 P28472 2/20 0.46
GABRA5 P31644 2/20 0.46
GABRA3 P34903 2/20 0.46
GABRA2 P47869 2/20 0.46
GABRB2 P47870 2/20 0.46
GABRA4 P48169 2/20 0.46
GABRE P78334 2/20 0.46
GABRA6 Q16445 2/20 0.46
GABRG1 Q8N1C3 2/20 0.46
GABRG3 Q99928 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL911001 1.00 FOLH1 (0.57) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL909914 1.00 FOLH1 (0.57) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL22316164 0.87 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL2447755 0.86 FOLH1 (0.67) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL25453237 0.85 FOLH1 (0.45) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL21152805 0.85 FOLH1 (0.45) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL18289215 0.85 FOLH1 (0.41) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL4655466 0.85 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL14765596 0.85 FOLH1 (0.45) FOLH1NAALAD2RIMKLAGGHCYP1A2
SCHEMBL4998037 0.85 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGGHCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ NATIONAL INSTITUTES OF HEALTH 2023-05-11 US disclosed
CN-101969920-A Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same SHISEIDO CO LTD 2011-02-09 CN disclosed
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same SHISEIDO COMPANY LTD. (JP) 2011-01-06 US disclosed
EP-2255780-A1 PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME Shiseido Company, Ltd. (JP) 2010-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same CUTA, GLRA3, ARGLU1 FOLH1 4099/4885NAALAD2 1692/4885RIMKLA 881/4885
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ HAVCR2, CD44, ENGASE FOLH1 2246/4885NAALAD2 93/4885RIMKLA 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.